Diagnosis and therapy of polycythemia vera

Seminars in Thrombosis and Hemostasis

Volumn 32, Issue 3, 2006, Pages 267-275

  Lengfelder, Eva ^a   Merx, Kirsten ^a   Hehlmann, Rüdiger ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Diagnosis; Leukemia; Myelofibrosis; Polycythemia vera; Therapy; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ALKYLATING AGENT; ALPHA INTERFERON; ANAGRELIDE; ANTITHROMBOCYTIC AGENT; BUSULFAN; CHLORAMBUCIL; DIPYRIDAMOLE; HYDROXYUREA; IMATINIB; MOLECULAR MARKER; PHOSPHORUS; PIPOBROMAN; PLACEBO; PROTEIN TYROSINE KINASE;

BONE MARROW TRANSPLANTATION; CELL PROLIFERATION; DRUG SAFETY; ERYTHROID CELL; GENE; GENE MUTATION; HEMATOPOIETIC STEM CELL; HIGH RISK PATIENT; HUMAN; JAK2 GENE; MYELOFIBROSIS; PHLEBOTOMY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SPLENECTOMY; STEM CELL TRANSPLANTATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS;

DRUG THERAPY; HUMANS; PHLEBOTOMY; POLYCYTHEMIA VERA; THROMBOSIS;

EID: 33646491601     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-939438     Document Type: Review

References (51)

1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 1951;6:372-375
2. Pierre R, Imbert M, Thiele J, Vardiman J, Brunning R, Flandrin G. Polycythemia vera. In: Jaffe E, Harris N, Stein H, Vardiman J, eds. Pathology and Genetics. Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:32-34
3. Thiele J, Kvasnicka HM, Fischer R, Diehl V. Histochemistry and morphometry on bone marrow specimens in chronic myeloproliferative disorders - aids to diagnosis and classification. Ann Hematol 1999;78:495-506
4. Silva M, Richard C, Benito A, Sanz C, Olalla I, Fernandez-Luna L. Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N Engl J Med 1998;338:564-571
5. Moliterno A, Hankins D, Spivak J. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N Engl J Med 1998;338:572-580
6. Klippel S, Strunck S, Temerinac S, et al. Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis. Blood 2003;102:3569-3574
7. Teofili L, Martini M, Luongo M, et al. Overexpression of the polycythemia rubra vera-1 gene in essential thrombocythemia. J Clin Oncol 2002;20:4249-4254
8. Palmqvist L, Goerttler P, Wasslavik C, et al. Comparison of methods for polycythemia rubra vera-1 mRNA quantification in whole-blood leukocytes and purified granulocytes. Clin Chem 2004;50:644-647
9. Emig M, Ernst T, Schenk T, et al. Relationship of PRV1 expression and JAK2 V617F mutations in chronic myeloproliferative disorders. Onkologie 2005;28(suppl 3):136 (abst 409)
10. Kralovics R, Passamonti F, Buser A, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-1790
11. Baxter E, Scott L, Campbell P, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-1061
12. James C, Ugo V, Couédic J, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-1148
13. Levine R, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-397
14. Jones A, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005;106:2162-2168
15. Gruppo Italiano Studio Polycythemia vera. The natural history of 1213 patients followed for 20 years. Ann Intern Med 1995;123:656-664
16. Najean Y, Dresch C, Rain JD. The very-long-term course of polycythemia: a complement to the previously published data of the polycythemia vera study group. Br J Haematol 1994;86:233-235
17. Rozman C, Giralt M, Feliu E, Rubio D, Cortés MT. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 1991;67:2658-2663
18. Passamonti F, Malabarba L, Orlandi E, et al. Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. Haematologica 2003;88:13-18
19. Najean Y, Mugnier P, Dresch C, Rain J. Polycythemia vera in young people. An analysis of 58 cases diagnosed before 40 years. Br J Haematol 1987;67:285-291
20. Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 1981;304:441-447
21. Berk PD, Goldberg JD, Donovan PD, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycythemia vera based on polycythemia vera study group protocols. Semin Hematol 1986;23:132-143
22. Messinezy M, Pearson TC. Incidence of myelofibrosis following treatment of primary polycythaemia by venesection. Br J Haematol 1995;89:228-229
23. Haanen C, Mathé G, Hayat M. Treatment of polycythemia vera by radiophosphorus or busulfan: a randomized trial. Br J Cancer 1981;44:75-80
24. 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. Blood 1997;89:2319-2327
25. Fruchtman SM, Mack K, Kaplan ME, Peterson P, Berk PD, Wasserman LR. From efficacy to safety: a polycythemia vera study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol 1997;34:17-23
26. Tatarsky I, Sharon R. Management of polycythemia vera with hydroxyurea. Semin Hematol 1997;34:24-28
27. Najean Y, Rain JD, for the French Polycythemia Study Group. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 1997;90:3370-3377
28. Finazzi G, Ruggeri M, Rodheghiero F, Barbui T. Second malignancies in patients with essential thrombocythemia treated with busulphan and hydroxyurea: long-term follow up of a randomized trial. Br J Haematol 2000;110:577-583
29. Finazzi G, Caruso V, Marchioli R, et al. ECLAP Investigators. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 2005;105:2664-2670
30. Brusamolino E, Salvaneschi L, Canevari A, Bernasconi C. Efficacy trial of pipobroman in polycythemia vera and incidence of acute leukemia. J Clin Oncol 1984;2:558-561
31. Petti MC, Spadea A, Avvisati G, et al. Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991). Leukemia 1998;12:869-874
32. Passamonti F, Brusalimo E, Lazzarino M, et al. Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients. Haematologica 2000;85:1011-1018
33. Kiladjian JJ, Gardin C, Renoux M, Bruno F, Bernard JF. Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy. Hematol J 2003;4:198-207
34. Lengfelder E, Berger U, Hehlmann R. Interferon α in the treatment of polycythemia vera. Ann Hematol 2000;79:103-109
35. Gilbert HS. Long term treatment of myeloproliferative disease with interferon-α-2b. Cancer 1998;83:1205-1213
36. Merx K, Fabarius A, Pahl H, et al. Pegylated interferon alpha (PegIntron) in patients with polycythemia vera. A prospective multicenter phase II Study. Onkologie 2004;27(suppl 3):74 (abst O 363)
37. Anagrelide study group. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med 1992; 92:69-76
38. Fruchtman SM. Treatment paradigms in the management of myeloproliferative disorders. Semin Hematol 2004;41 (suppl 3):18-22
39. Storen E, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood 2001;97:863-866
40. Harrison CN, Campbell PJ, Buck G, et al. United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353:33-45
41. Silver RT. Imatinib mesylate (Gleevec™) reduces phlebotomy requirements in polycythemia vera. Leukemia 2003;17:1186-1187
42. Silver RT, Fruchtman SM, Feldman EJ, Spivak JL, Salvado AJ. Imatinib mesylate (GLEEVEC) is effective in the treatment of polycythemia vera: a multi-institutional clinical trial. Blood 2004;104:(abst 656)
43. Hasselbalch HC, Pedersen M, Bostrom H. Imatinib mesylate therapy reduces phlebotomy requirements in polycythemia vera. Blood 2003;102:(abst 5087)
44. Borthakur G, Kantarjian H, Vesrtovsek S, et al. Imatinib mesylate therapy for patients with polycythemia vera. Blood 2004;104:(abst 1527)
45. Hasselbalch HC, Larsen TS, Henriksen AS, et al. Imatinib mesylate in polycythemia vera. A Heterogeneous Response pattern but a consistent reduction in phlebotomy requirements. Blood 2004;104:(abst 4747)
46. Kuriakose P, Shurafa MS. A phase II trial of imatinib mesylate (Gleevec) in myeloproliferative disorders. Blood 2004;104:(abst 4765)
47. Jones CM, Dickinson TM. Polycythemia vera responds to imatinib mesylate. Am J Med Sci 2003;325:149-152
48. Merx K, Maywald O, Fabarius A, et al. Imatinib (Glivcc®) therapy in patients with polycythemia vera. Interim analyses of an open label phase II trial. Onkologie 2005;27(suppl 3):80 (abst 235)
49. Tartaglia A, Goldberg JD, Berk PD, Wasserman LR. Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. Semin Hematol 1986;23:172-176
50. Gruppo Italiano Studio Polycythemia vera. Low dose aspirin in polycythemia vera: a pilot study. Br J Haematol 1997;97:453-456
51. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low dose aspirin in polycythemia vera. N Engl J Med 2004;350:114-124